DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Veliparib is an investigational drug.
There have been 92 clinical trials for Veliparib. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2014.
The most common disease conditions in clinical trials are Breast Neoplasms, Ovarian Neoplasms, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), AbbVie, and AbbVie (prior sponsor, Abbott).
There are thirty US patents protecting this investigational drug and one hundred and ninety-six international patents.
Recent Clinical Trials for Veliparib
|A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer||AbbVie||Phase 1|
|Veliparib, Radiation Therapy, and Temozolomide in Treating Participants With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600E Mutations||National Cancer Institute (NCI)||Phase 2|
|Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia||National Cancer Institute (NCI)||Phase 2|
Top disease conditions for Veliparib
Top clinical trial sponsors for Veliparib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Veliparib||Start Trial||Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines||Signal Pharmaceuticals, LLC (San Diego, CA)||Start Trial|
|Veliparib||Start Trial||System and method for diagnosis and treatment||Pop Test Oncology Limited Liability Company (Cliffside Park, NJ)||Start Trial|
|Veliparib||Start Trial||DNA2 inhibitors for cancer treatment||City of Hope (Duarte, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Veliparib||European Patent Office||3131552||2034-04-16||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|